NURS Hydreight Technologies Inc.
Hydreight Technologies Inc. operates in the digital health technology sector in the United States. The company develops a proprietary telemedicine service that allows users to book confidential health and wellness, and/or medical services through a mobile application. It also provides consulting and advice in setting up health and wellness services, including assistance with finding experienced advisors in the areas of medical and privacy law, among others; medical liability insurance; pharmaceutical IV programs vetted by duly licensed pharmacists; procedural guides with respect to various services, such as a range of IV therapy treatments, GLP1, NAD, Botox, and fillers; and hiring, on-boarding, training, marketing, branding, payroll, and other accounting services. In addition, the company offers an online pharmacy, which allows its network of medical practitioners to purchase pharmacy products from federally regulated pharmacies. Hydreight Technologies Inc. is headquartered in Las Vegas, Nevada.…
Industry Peers
Health Information ServicesKey Statistics
About Hydreight Technologies (CVE: NURS)
›
Hydreight Technologies (CVE: NURS) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Health Information Services industry, part of the Healthcare sector.
The shares were at 3.150 CAD on 19 November 2026, down 36.0% over 52 weeks. Its 52-week range is 2.380 CAD to 5.400 CAD: the price is 41.7% below the high and 32.4% above the low.
At a market capitalisation of 169.07M CAD, it trades at 24.2 times trailing earnings and 6.6 times forward earnings. The median trailing P/E of its 14 largest Health Information Services peers is 42.1, a discount of 42% for NURS.
Hydreight Technologies reports return on equity of 8.6%, an operating margin of 9.0% and revenue up 421.4% year over year.
It holds more cash than debt, a net cash position of 11.18M CAD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 3 analysts cover the stock; their mean price target of 7.917 CAD is 151.3% above the current price. The next earnings report is expected on 26 November 2026.